CircPrimer 2.0: a software for annotating circRNAs and predicting translation potential of circRNAs von Zhong, Shanliang, Feng, Jifeng

Volltext

Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures von Feng, Bing, Wu, Jianzhong, Shen, Bo, Jiang, Feng, Feng, Jifeng

Volltext

Response to Letter to the Editor From Shaorong Yu and Jifeng Feng von Garassino, Marina C, Faivre-Finn, Corinne

Volltext

CircPrimer: a software for annotating circRNAs and determining the specificity of circRNA primers von Zhong, Shanliang, Wang, Jinyan, Zhang, Qian, Xu, Hanzi, Feng, Jifeng

Volltext

A synthetic aperture for land controlled-source electromagnetic surveys von Zhang, Jifeng, Huang, Rihua, Feng, Bing

Volltext

LncRNA HOXA11‐AS drives cisplatin resistance of human LUAD cells via modulating miR‐454‐3p/Stat3 von Zhao, Xia, Li, Xiaoyou, Zhou, Leilei, Ni, Jie, Yan, Wenyue, Ma, Rong, Wu, Jianzhong, Feng, Jifeng, Chen, Ping

Volltext

C-reactive protein and cancer risk: a pan-cancer study of prospective cohort and Mendelian randomization analysis von Zhu, Meng, Ma, Zhimin, Zhang, Xu, Hang, Dong, Yin, Rong, Feng, Jifeng, Xu, Lin, Shen, Hongbing

Volltext

Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial von Wang, Zi-Xian, Cui, Chengxu, Yao, Jun, Zhang, Yanqiao, Li, Mengxia, Feng, Jifeng, Yang, Shujun, Fan, Yun, Shi, Jianhua, Zhang, Xizhi, Shen, Lin, Shu, Yongqian, Wang, Cailian, Dai, Tianyang, Mao, Teng, Chen, Long, Guo, Zengqing, Liu, Bo, Pan, Hongming, Cang, Shundong, Jiang, Yi, Wang, Junye, Ye, Min, Chen, Zhendong, Jiang, Da, Lin, Qin, Ren, Wei, Wang, Junsheng, Wu, Lin, Xu, Yong, Miao, Zhanhui, Sun, Meili, Xie, Conghua, Liu, Ying, Wang, Qifeng, Zhao, Lina, Li, Qi, Huang, Canhong, Jiang, Ke, Yang, Kunyu, Li, Daojun, Liu, Yunpeng, Zhu, Zhitu, Chen, Rixin, Jia, Liqun, Li, Wei, Liao, Wangjun, Liu, Hong-Xu, Ma, Daiyuan, Ma, Jie, Qin, Yanru, Shi, Zhihong, Wei, Qichun, Xiao, Ke, Zhang, Yan, Zhang, Ying, Chen, Xin, Dai, Guanghai, He, Jianxing, Li, Junhe, Li, Guanghui, Liu, Yong, Liu, Zhihua, Yuan, Xianglin, Zhang, Junping, Fu, Zhichao, He, Yifu, Ju, Fang, Liu, Zheng, Tang, Peng, Wang, Tiejun, Wang, Weibo, Zhang, Jing, Luo, Xianming, Tang, Xiongwen, May, Rena, Feng, Hui, Yao, Sheng, Keegan, Patricia, Xu, Rui-Hua, Wang, Feng

Volltext

The role of LncRNAs in tumor immunotherapy von Pan, Xuan, Li, Chenchen, Feng, Jifeng

Volltext

Clinical significance of preoperative CALLY index for prognostication in patients with esophageal squamous cell carcinoma undergoing surgery von Feng, Jifeng, Wang, Liang, Yang, Xun, Chen, Qixun

Volltext

LncRNA KTN1-AS1 promotes the progression of non-small cell lung cancer via sponging of miR-130a-5p and activation of PDPK1 von Li, Chenchen, Zhao, Wei, Pan, Xuan, Li, Xiaoyou, Yan, Fei, Liu, Siwen, Feng, Jifeng, Lu, Jianwei

Volltext

EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells von Yu, Shaorong, Sha, Huanhuan, Qin, Xiaobing, Chen, Yan, Li, Xiaoyou, Shi, Meiqi, Feng, Jifeng

Volltext

A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9) von Lv, Yan, Ma, Xiao, Ma, Yuxin, Du, Yuxin, Feng, Jifeng

Volltext

LncRNA SNHG15: A new budding star in human cancers von Shuai, You, Ma, Zhonghua, Lu, Jianwei, Feng, Jifeng

Volltext

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label... von Wu, Yi-Long, Prof, Zhou, Caicun, Prof, Hu, Cheng-Ping, Prof, Feng, Jifeng, Prof, Lu, Shun, Prof, Huang, Yunchao, Prof, Li, Wei, Prof, Hou, Mei, Prof, Shi, Jian Hua, Prof, Lee, Kye Young, Prof, Xu, Chong-Rui, MD, Massey, Dan, MSc, Kim, Miyoung, MD, Shi, Yang, MD, Geater, Sarayut L, MD

Volltext

Preoperative inflammatory burden index for prognostication in esophageal squamous cell carcinoma undergoing radical resection von Zhao, Qiang, Wang, Liang, Yang, Xun, Feng, Jifeng, Chen, Qixun

Volltext

Adjuvant immunotherapy after neoadjuvant immunochemotherapy and esophagectomy for esophageal squamous cell carcinoma: a real-world study von Feng, Jifeng, Wang, Liang, Yang, Xun, Chen, Qixun

Volltext

LncRNA SNHG15 regulates EGFR-TKI acquired resistance in lung adenocarcinoma through sponging miR-451 to upregulate MDR-1 von Huang, Jiayuan, Pan, Banzhou, Xia, Guohao, Zhu, Jingni, Li, Chenchen, Feng, Jifeng

Volltext

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple‐negative breast cancer von Hu, Xichun, Zhang, Jian, Xu, Binghe, Jiang, Zefei, Ragaz, Joseph, Tong, Zhongsheng, Zhang, Qingyuan, Wang, Xiaojia, Feng, Jifeng, Pang, Danmei, Fan, Minhao, Li, Jin, Wang, Biyun, Wang, Zhonghua, Zhang, Qunling, Sun, Si, Liao, Chunmei

Volltext

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label,... von Zhou, Caicun, Prof, Wu, Yi-Long, Prof, Chen, Gongyan, Prof, Feng, Jifeng, Prof, Liu, Xiao-Qing, Prof, Wang, Changli, Prof, Zhang, Shucai, Prof, Wang, Jie, Prof, Zhou, Songwen, MD, Ren, Shengxiang, MD, Lu, Shun, Prof, Zhang, Li, Prof, Hu, Chengping, Prof, Hu, Chunhong, Prof, Luo, Yi, Prof, Chen, Lei, Prof, Ye, Ming, Prof, Huang, Jianan, Prof, Zhi, Xiuyi, Prof, Zhang, Yiping, Prof, Xiu, Qingyu, Prof, Ma, Jun, Prof, You, Changxuan, Prof

Volltext